FDA Adverse Event Malfunction Summary report: N

RAYONE EMV

MDR report key: 18823456 · Received March 3, 2024

Report

Report Number
3012304651-2024-00049
Event Type
Malfunction
Date Received
March 3, 2024
Report Date
June 10, 2024
Manufacturer
RAYNER INTRAOCULAR LENSES LIMITED
Product Code
HQL
UDI-DI
05029867006685
PMA / PMN Number
P060011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
WA, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

THE REFERENCE C240375 HAS BEEN ALLOCATED TO THIS CASE BY RAYNER. THE EVENT DESCRIPTION PROVIDED STATES THAT THE PATIENT UNDERWENT IMPLANTATION OF A RAYONE EMV RAO200E IOL ON (B)(6) 2023 AND ON AN UNKNOWN DATE POST-OPERATIVELY PRESENTED WITH OPACIFICATION OF THE IOL. THE PATIENT'S VISUAL ACUITY WAS IMPACTED AS A RESULT OF THE ONSET OF OPACIFICATION. OPACIFICATION IS REPORTED TO HAVE BEEN UNRESOLVED BY YAG THEREFORE NECESSITATING EXPLANTATION. THE IOL WAS EXPLANTED AND EXCHANGED ON AN UNKNOWN DATE POST-OPERATIVLEY. THE TIMING OF ONSET IS QUITE SOON FOR A POTENTIAL POSTERIOR CAPSULE OPACIFICATION (PCO) CASE AS THIS IS MORE USUALLY NOTED IN THE 2 TO 5 YEAR DATE RANGE AFTER IMPLANTATION DUE TO THE SLOW GROWTH RATE OF LECS. THIS ALSO APPLIES TO TYPICAL CASES OF POST-OPERATIVE OPACIFICATION OR CALCIFICATION (WHEREBY CALCIUM PHOSPHATE DEPOSITS ARE IDENTIFIED ON THE LENS VIA SCANNING ELECTRON MICROSCOPY ANALYSIS). THERE ARE CERTAIN PATIENT CONDITIONS THAT MAY INCREASE THE LIKELIHOOD OF DEPOSITS DEVELOPING WITHIN THE EYE POST-OPERATIVELY INCLUDING BUT NOT LIMITED TO; GLAUCOMA, DIABETES, PSEUDOEXFOLIATION SYNDROME. THERE IS INSUFFICIENT EVIDENCE AND INFORMATION AVAILABLE AT THIS TIME TO ESTABLISH ROOT CAUSE OF THE REPORTED "OPACIFICATION". RAYNER IS FOLLOWING UP TO OBTAIN ADDITIONAL EVIDENCE AND INFORMATION VIA ITS REPRESENTATIVES IN THE US TO FACILITATE FURTHER INVESTIGATION OF THIS EVENT.

Additional Manufacturer Narrative · 0

THE REFERENCE (B)(4) HAS BEEN ALLOCATED TO THIS CASE BY RAYNER. THE EVENT DESCRIPTION PROVIDED STATES THAT THE PATIENT UNDERWENT IMPLANTATION OF A RAYONE EMV RAO200E IOL ON (B)(6) 2023 AND ON AN UNKNOWN DATE POST-OPERATIVELY PRESENTED WITH OPACIFICATION OF THE IOL. THE PATIENT'S VISUAL ACUITY WAS IMPACTED AS A RESULT OF THE ONSET OF OPACIFICATION. OPACIFICATION IS REPORTED TO HAVE BEEN UNRESOLVED BY YAG THEREFORE NECESSITATING EXPLANTATION. THE IOL WAS EXPLANTED AND EXCHANGED ON AN UNKNOWN DATE POST-OPERATIVLEY. THE TIMING OF ONSET IS QUITE SOON FOR A POTENTIAL POSTERIOR CAPSULE OPACIFICATION (PCO) CASE AS THIS IS MORE USUALLY NOTED IN THE 2 TO 5 YEAR DATE RANGE AFTER IMPLANTATION DUE TO THE SLOW GROWTH RATE OF LECS. THIS ALSO APPLIES TO TYPICAL CASES OF POST-OPERATIVE OPACIFICATION OR CALCIFICATION (WHEREBY CALCIUM PHOSPHATE DEPOSITS ARE IDENTIFIED ON THE LENS VIA SCANNING ELECTRON MICROSCOPY ANALYSIS). THERE ARE CERTAIN PATIENT CONDITIONS THAT MAY INCREASE THE LIKELIHOOD OF DEPOSITS DEVELOPING WITHIN THE EYE POST-OPERATIVELY INCLUDING BUT NOT LIMITED TO; GLAUCOMA, DIABETES, PSEUDOEXFOLIATION SYNDROME. THE EXPLANTED LENS WAS RETAINED AND RETURNED TO RAYNER. AS THE REPORT CONCERNED THE POST-OPERATIVE ONSET OF OPACIFICATION, THE RETURNED EXPLANTED LENS WAS SENT TO A THIRD PARTY INDEPENDENT LABORATORY TO UNDERGO ANALYSIS. SCANNING ELECTRON MICROSCOPY DID NOT SHOW ANY VISUAL EVIDENCE OF CALCIFICATION. ENERGY DISPERSIVE X-RAY SPECTROSCOPY DID NOT INDICATE ANY ELEMENTAL (CALCIUM AND PHOSPHATE) EVIDENCE OF CALCIFICATION. ALIZIRIN RED TESTING WAS PERFORMED AS AN ADDITIONAL ACTION IN THIS CASE AND THIS DID NOT BIND OR STRAIN ANY CALCIUM ON THE EXPLANTED LENS. THE ANALYSIS PERFORMED CONFIRMS THAT THE LENS IS FREE OF CALCIFICATION. THERE IS NO FAULT OF THE RAYNER DEVICE.

Description of Event or Problem · 0

ON 13TH FEBRUARY 2024, RAYNER RECEIVED NOTIFICATION FROM A US HEALTHCARE FACILITY OF AN EVENT THAT OCCURRED FOLLOWING IMPLANTATION OF A RAYONE EMV RAO200E. THE EVENT DESCRIPTION PROVIDED STATES THAT POST-OPERATIVELY OPACIFICATION OF THE IOL WAS OBSERVED AND THAT VISUAL ACUITY DECLINED AS A RESULT NECESSITATING IOL EXPLANTATION.

Description of Event or Problem · 0

ON 13TH FEBRUARY 2024, RAYNER RECEIVED NOTIFICATION FROM A US HEALTHCARE FACILITY OF AN EVENT THAT OCCURRED FOLLOWING IMPLANTATION OF A RAYONE EMV RAO200E. THE EVENT DESCRIPTION PROVIDED STATES THAT POST-OPERATIVELY OPACIFICATION OF THE IOL WAS OBSERVED AND THAT VISUAL ACUITY DECLINED AS A RESULT NECESSITATING IOL EXPLANTATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
165067 RAYONE EMV RAYONE EMV HQL RAYNER INTRAOCULAR LENSES LIMITED RAO200E 06193468 05029867006685

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown